1. The Synthesis of Haptens and Their Use for the Development of Monoclonal Antibodies for Treating Methamphetamine Abuse.
- Author
-
F. Ivy Carroll, Philip Abraham, Paul K. Gong, Ramakrishna R. Pidaparthi, Bruce E. Blough, Yingni Che, Amber Hampton, Melinda Gunnell, Jackson O. Lay, Eric C. Peterson, and S. Michael Owens
- Subjects
- *
HAPTENS , *MONOCLONAL antibodies , *METHAMPHETAMINE abuse , *AMPHETAMINES , *ECSTASY (Drug) , *PSYCHOSES , *IMMUNOTHERAPY , *THERAPEUTICS - Abstract
In addition to addiction, the repeated use of (+)-methamphetamine [(+)-METH], (+)-amphetamine [(+)-AMP], or (±)-3,4-methylenedioxymethamphetamine ((±)-MDMA, commonly called ecstasy) can lead to life-threatening medical problems including cardiovascular injury, severe depression, and psychosis. Currently, there are no specific pharmacotherapies to treat these medical problems. In this study, we report the design and synthesis of two haptens, (S)-(+)-3-(9-carboxynonyloxy)methamphetamine (3a, (+)-METH MO10) and (S)-(+)-3-(5-carboxypentyloxy)methamphetamine (3b, (+)-METH MO6), and their use in generating high affinity (low KDvalue) monoclonal antibodies (mAbs) against (+)-METH, (+)-AMP, and/or (+)-MDMA. On the basis of results from the determination of mAb KDvalues and ligand specificity, the mAbs generated from hapten 3ashowed the greatest promise for generating active and passive immunotherapies for treating overdose or addiction from (+)-METH-like stimulants. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF